Literature DB >> 24184606

Decreased cell proliferation and higher oxidative stress in fibroblasts from Down Syndrome fetuses. Preliminary study.

Amparo Gimeno1, José Luis García-Giménez, Laura Audí, Nuria Toran, Pilar Andaluz, Francisco Dasí, José Viña, Federico V Pallardó.   

Abstract

Down Syndrome is the most common chromosomal disease and is also known for its decreased incidence of solid tumors and its progeroid phenotype. Cellular and systemic oxidative stress has been considered as one of the Down Syndrome phenotype causes. We correlated, in a preliminary study, the fibroblast proliferation rate and different cell proliferation key regulators, like Rcan1 and the telomere length from Down Syndrome fetuses, with their oxidative stress profile and the Ribonucleic acid and protein expression of the main antioxidant enzymes together with their activity. Increased oxidized glutathione/glutathione ratio and high peroxide production were found in our cell model. These results correlated with a distorted antioxidant shield. The messenger RNA (SOD1) and protein levels of copper/zinc superoxide dismutase were increased together with a decreased mRNA expression and protein levels of glutathione peroxidase (GPx). As a consequence the [Cu/ZnSOD/(catalase+GPx)] activity ratio increases which explains the oxidative stress generated in the cell model. In addition, the expression of thioredoxin 1 and glutaredoxin 1 is decreased. The results obtained show a decreased antioxidant phenotype that correlates with increased levels of Regulator of calcineurin 1 and attrition of telomeres, both related to oxidative stress and cell cycle impairment. Our preliminary results may explain the proneness to a progeroid phenotype.
© 2013.

Entities:  

Keywords:  BrdU; Cu/Zn superoxide dismutase; Cu/ZnSOD; DHR; DS; Down Syndrome; GAPDH; GPx; Glutathione; Grx1; Mn superoxide dismutase; MnSOD; Progeroid; ROS; Rcan1; Superoxide dismutase; TL; Telomere length; Thioredoxin; Trx1; bromodeoxyuridine; dihydrorhodamine; glutaredoxin 1; glutathione peroxidase; glyceraldehyde-3-phosphate dehydrogenase; reactive oxygen species; telomere length; thioredoxin 1

Mesh:

Substances:

Year:  2013        PMID: 24184606     DOI: 10.1016/j.bbadis.2013.10.014

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  16 in total

1.  Telomere shortening in Down syndrome patients--when does it start?

Authors:  Aleksandra Gruszecka; Przemysław Kopczyński; Dorota Cudziło; Natalia Lipińska; Aleksandra Romaniuk; Wojciech Barczak; Natalia Rozwadowska; Ewa Totoń; Błażej Rubiś
Journal:  DNA Cell Biol       Date:  2015-03-18       Impact factor: 3.311

2.  Challenges and Opportunities for Translation of Therapies to Improve Cognition in Down Syndrome.

Authors:  Sarah E Lee; Monica Duran-Martinez; Sabina Khantsis; Diana W Bianchi; Faycal Guedj
Journal:  Trends Mol Med       Date:  2019-11-07       Impact factor: 11.951

Review 3.  Synthetic combinations of missense polymorphic genetic changes underlying Down syndrome susceptibility.

Authors:  Rebecca A Jackson; Mai Linh Nguyen; Angela N Barrett; Yuan Yee Tan; Mahesh A Choolani; Ee Sin Chen
Journal:  Cell Mol Life Sci       Date:  2016-05-31       Impact factor: 9.261

4.  Redox proteomics analysis of HNE-modified proteins in Down syndrome brain: clues for understanding the development of Alzheimer disease.

Authors:  Fabio Di Domenico; Gilda Pupo; Antonella Tramutola; Alessandra Giorgi; Maria Eugenia Schininà; Raffaella Coccia; Elizabeth Head; D Allan Butterfield; Marzia Perluigi
Journal:  Free Radic Biol Med       Date:  2014-03-25       Impact factor: 7.376

Review 5.  Cell models for Down syndrome-Alzheimer's disease research.

Authors:  Yixing Wu; Nicole R West; Anita Bhattacharyya; Frances K Wiseman
Journal:  Neuronal Signal       Date:  2022-04-08

Review 6.  Polyubiquitinylation Profile in Down Syndrome Brain Before and After the Development of Alzheimer Neuropathology.

Authors:  Antonella Tramutola; Fabio Di Domenico; Eugenio Barone; Andrea Arena; Alessandra Giorgi; Laura di Francesco; Maria Eugenia Schininà; Raffaella Coccia; Elizabeth Head; D Allan Butterfield; Marzia Perluigi
Journal:  Antioxid Redox Signal       Date:  2016-10-26       Impact factor: 8.401

7.  Apigenin as a Candidate Prenatal Treatment for Trisomy 21: Effects in Human Amniocytes and the Ts1Cje Mouse Model.

Authors:  Faycal Guedj; Ashley E Siegel; Jeroen L A Pennings; Fatimah Alsebaa; Lauren J Massingham; Umadevi Tantravahi; Diana W Bianchi
Journal:  Am J Hum Genet       Date:  2020-10-23       Impact factor: 11.025

8.  Intracellular oxidant activity, antioxidant enzyme defense system, and cell senescence in fibroblasts with trisomy 21.

Authors:  Víctor Rodríguez-Sureda; Ángel Vilches; Olga Sánchez; Laura Audí; Carmen Domínguez
Journal:  Oxid Med Cell Longev       Date:  2015-03-17       Impact factor: 6.543

9.  mTOR hyperactivation in Down Syndrome underlies deficits in autophagy induction, autophagosome formation, and mitophagy.

Authors:  Matteo Bordi; Sandipkumar Darji; Yutaka Sato; Marian Mellén; Martin J Berg; Asok Kumar; Ying Jiang; Ralph A Nixon
Journal:  Cell Death Dis       Date:  2019-07-22       Impact factor: 8.469

10.  The burden of trisomy 21 disrupts the proteostasis network in Down syndrome.

Authors:  Stefanos Aivazidis; Christina M Coughlan; Abhishek K Rauniyar; Hua Jiang; L Alexander Liggett; Kenneth N Maclean; James R Roede
Journal:  PLoS One       Date:  2017-04-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.